These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

514 related items for PubMed ID: 9459623

  • 1. Thyroid vascularization by color doppler ultrasonography in Graves' disease. Changes related to different phases and to the long-term outcome of the disease.
    Baldini M, Castagnone D, Rivolta R, Meroni L, Pappalettera M, Cantalamessa L.
    Thyroid; 1997 Dec; 7(6):823-8. PubMed ID: 9459623
    [Abstract] [Full Text] [Related]

  • 2. Differentiation of postpartum Graves' thyrotoxicosis from postpartum destructive thyrotoxicosis using antithyrotropin receptor antibodies and thyroid blood flow.
    Ide A, Amino N, Kang S, Yoshioka W, Kudo T, Nishihara E, Ito M, Nakamura H, Miyauchi A.
    Thyroid; 2014 Jun; 24(6):1027-31. PubMed ID: 24400892
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Prediction of relapse after antithyroid drug therapy of Graves' disease: value of color Doppler sonography.
    Saleh A, Cohnen M, Fürst G, Mödder U, Feldkamp J.
    Exp Clin Endocrinol Diabetes; 2004 Oct; 112(9):510-3. PubMed ID: 15505758
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Color Doppler sonography in Graves' disease: value in assessing activity of disease and predicting outcome.
    Castagnone D, Rivolta R, Rescalli S, Baldini MI, Tozzi R, Cantalamessa L.
    AJR Am J Roentgenol; 1996 Jan; 166(1):203-7. PubMed ID: 8571877
    [Abstract] [Full Text] [Related]

  • 7. Sensitive thyrotropin and thyrotropin-receptor antibody determinations one month after discontinuation of antithyroid drug treatment as predictors of relapse in Graves' disease.
    Quadbeck B, Hoermann R, Roggenbuck U, Hahn S, Mann K, Janssen OE, Basedow Study Group.
    Thyroid; 2005 Sep; 15(9):1047-54. PubMed ID: 16187913
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Thyroid blood flow evaluation by color-flow Doppler sonography distinguishes Graves' disease from Hashimoto's thyroiditis.
    Vitti P, Rago T, Mazzeo S, Brogioni S, Lampis M, De Liperi A, Bartolozzi C, Pinchera A, Martino E.
    J Endocrinol Invest; 1995 Dec; 18(11):857-61. PubMed ID: 8778158
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The significance of thyroid blood flow at the inferior thyroid artery as a predictor for early Graves' disease relapse.
    Ueda M, Inaba M, Kumeda Y, Nagasaki T, Hiura Y, Tahara H, Onoda N, Ishikawa T, Nishizawa Y.
    Clin Endocrinol (Oxf); 2005 Dec; 63(6):657-62. PubMed ID: 16343100
    [Abstract] [Full Text] [Related]

  • 12. Serum thyrotropin receptor antibodies concentrations in patients with Graves' disease before, at the end of methimazole treatment, and after drug withdrawal: evidence that the activity of thyrotropin receptor antibody and/or thyroid response modify during the observation period.
    Carella C, Mazziotti G, Sorvillo F, Piscopo M, Cioffi M, Pilla P, Nersita R, Iorio S, Amato G, Braverman LE, Roti E.
    Thyroid; 2006 Mar; 16(3):295-302. PubMed ID: 16571093
    [Abstract] [Full Text] [Related]

  • 13. Prognostic value of thyrotropin receptor antibodies (TRAb) in Graves' disease: a 120 months prospective study.
    Cappelli C, Gandossi E, Castellano M, Pizzocaro C, Agosti B, Delbarba A, Pirola I, De Martino E, Rosei EA.
    Endocr J; 2007 Dec; 54(5):713-20. PubMed ID: 17675761
    [Abstract] [Full Text] [Related]

  • 14. Effect of methimazole with or without exogenous L-thyroxine on serum concentrations of thyrotropin (TSH) receptor antibodies in patients with Graves' disease.
    Rittmaster RS, Zwicker H, Abbott EC, Douglas R, Givner ML, Gupta MK, Lehmann L, Reddy S, Salisbury SR, Shlossberg AH, Tan MH, York SE.
    J Clin Endocrinol Metab; 1996 Sep; 81(9):3283-8. PubMed ID: 8784084
    [Abstract] [Full Text] [Related]

  • 15. Thyroid hypoechogenicity after methimazole withdrawal in Graves' disease: a useful index for predicting recurrence?
    Zingrillo M, D'Aloiso L, Ghiggi MR, Di Cerbo A, Chiodini I, Torlontano M, Liuzzi A.
    Clin Endocrinol (Oxf); 1996 Aug; 45(2):201-6. PubMed ID: 8881453
    [Abstract] [Full Text] [Related]

  • 16. Administration of thyroxine in treated Graves' disease. Effects on the level of antibodies to thyroid-stimulating hormone receptors and on the risk of recurrence of hyperthyroidism.
    Hashizume K, Ichikawa K, Sakurai A, Suzuki S, Takeda T, Kobayashi M, Miyamoto T, Arai M, Nagasawa T.
    N Engl J Med; 1991 Apr 04; 324(14):947-53. PubMed ID: 1900575
    [Abstract] [Full Text] [Related]

  • 17. Relapse of Graves' disease after successful outcome of antithyroid drug therapy: results of a prospective randomized study on the use of levothyroxine.
    Hoermann R, Quadbeck B, Roggenbuck U, Szabolcs I, Pfeilschifter J, Meng W, Reschke K, Hackenberg K, Dettmann J, Prehn B, Hirche H, Mann K, Basedow Study Group.
    Thyroid; 2002 Dec 04; 12(12):1119-28. PubMed ID: 12593726
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Hypothyroidism during antithyroid drug treatment with methimazole is a favorable prognostic indicator in patients with Graves' disease.
    Choo YK, Yoo WS, Kim DW, Chung HK.
    Thyroid; 2010 Sep 04; 20(9):949-54. PubMed ID: 20629556
    [Abstract] [Full Text] [Related]

  • 20. Antithyroid drugs inhibit radioiodine-induced increases in thyroid autoantibodies in hyperthyroid Graves' disease.
    Nakazato N, Yoshida K, Mori K, Kiso Y, Sayama N, Tani JI, Nakagawa Y, Ito S.
    Thyroid; 1999 Aug 04; 9(8):775-9. PubMed ID: 10482369
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.